Standard Biotools Inc. (LAB) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Standard Biotools Inc. (LAB) stock forecast summary
Our AI ranks Standard Biotools Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Standard Biotools Inc. is a small-cap company with a market capitalization of $259M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/B Ratio of 0.48x is the lowest of the 43 peers that report one.
A per-ticker accuracy statistic for LAB is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LAB included.
Follow LAB freeLAB price chart and AI forecast
How LAB ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Standard Biotools Inc. (LAB) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | LAB | Rank |
|---|---|---|
| Market Cap | $259M | 60/60 |
| P/B Ratio | 0.48x | 43/43 |
| EPS | $-0.18 | – |
| Book Value/Share | $1.38 | – |
| Revenue/Share | $0.16 | – |
| FCF/Share | $-0.21 | – |
Profitability & Margins
| Metric | LAB | Rank |
|---|---|---|
| ROIC | -15.7% | 25/41 |
| Gross Margin | 53.1% | 25/29 |
| Operating Margin | -139.7% | 29/33 |
| EBT Margin | -137.9% | 35/40 |
| Tax Rate | 41.9% | – |
Financial Health
| Metric | LAB | Rank |
|---|---|---|
| Current Ratio | 9.10x | 11/50 |
| Quick Ratio | 8.80x | 2/37 |
| D/E Ratio | 0.16x | 34/43 |
| Financial Leverage | 1.16x | 35/43 |
| Interest Coverage | -6347.0x | 36/36 |
| Working Capital | $460M | 40/50 |
Cash Flow
| Metric | LAB | Rank |
|---|---|---|
| Operating Cash Flow | -$80M | 33/49 |
| Free Cash Flow | -$83M | 26/39 |
| Capital Spending | -$2M | 11/39 |
| FCF/Sales | -129.0% | 31/34 |
| CapEx/Sales | 3.5% | 14/34 |
Operational Efficiency
| Metric | LAB | Rank |
|---|---|---|
| Asset Turnover | 0.10x | 34/38 |
| Receivables Turnover | 4.1x | 25/34 |
| Inventory Turnover | 1.8x | 12/27 |
| Fixed Assets Turnover | 4.2x | 21/37 |
| Days Sales Outstanding | 90 days | 10/34 |
| Days Inventory | 208 days | 16/27 |
| Payables Period | 116 days | 14/23 |
| Cash Conversion Cycle | 182 days | 13/21 |
Income Statement
| Metric | LAB | Rank |
|---|---|---|
| Total Revenue | $64M | 38/39 |
| Operating Income | -$89M | 24/41 |
| R&D Expense | $13M | 48/48 |
| SG&A Expense | $78M | 35/35 |
| Cost of Goods Sold | $30M | 22/27 |
Dividend & Shareholder Information
| Metric | LAB | Rank |
|---|---|---|
| Shares Outstanding | 393M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $517M | 82.4% of assets |
| Cash & Short-term Investments | $270M | 43.1% of assets |
| Accounts Receivable | $16M | 2.5% of assets |
| Inventory | $17M | 2.7% of assets |
| Total Liabilities | $87M | 13.9% of assets |
| Short-term Debt | $47M | 7.5% of assets |
LAB quarterly financials and insider trading
Standard Biotools Inc. (LAB) industry peers
Companies classified under the same SEC industry code as Standard Biotools Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LAB Standard Biotools Inc. | ▼ | $259M |
| LLY Eli Lilly & Co | ▲ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.61B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▶ | $178.85B |
| PFE Pfizer Inc | ▲ | $161.87B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $128.50B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $78.54B |
| SNY Sanofi | ▼ | $48.46B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.98B |
| RPRX Royalty Pharma Plc | ▲ | $33.22B |
| ZTS Zoetis Inc. | ▼ | $31.26B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.72B |
| ZLAB Zai Lab Ltd | ▼ | $27.60B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.74B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.99B |
| UTHR United Therapeutics Corp | ▼ | $23.59B |
| INSM Insmed Inc | ▶ | $21.14B |
| VTRS Viatris Inc | ▶ | $20.15B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| SMMT Summit Therapeutics Inc. | ▶ | $13.67B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.70B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $9.37B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.57B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| ABVX Abivax S.A. | ▼ | $6.83B |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.79B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $6.18B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| BLRX Biolinerx Ltd. | ▶ | $5.67B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.25B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.90B |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
Where LAB sits on the market map
Standard Biotools Inc. (LAB) stock news
Loading...
Standard Biotools Inc. (LAB) stock forecast FAQ
What is the Standard Biotools Inc. (LAB) stock forecast?
Our AI ranks Standard Biotools Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Standard Biotools Inc. stock predictions?
A per-ticker accuracy statistic for LAB is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Standard Biotools Inc. forecasts updated?
Standard Biotools Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Standard Biotools Inc.'s industry peers?
60 issuers in our coverage, LAB included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.